Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Cetirizine Hydrochloride Syrup, 5 mg/5 mL. Total annual market sales for Cetirizine Hydrochloride Syrup were $146.3 million (IMS ? MAT: June 2006).
A research paper published in the November 2006 edition of BJOG: An International Journal of Obstetrics and Gynaecology reveals seasonal and environmental variations can result in higher incidences of premature births.
Governor Mike Huckabee of Arkansas and Pfizer Inc today announced the formation of Balance It Out: Arkansas, a new school-based community program to reduce the number of children who are overweight or at risk of becoming overweight, effectively diminishing their risk of developing chronic illness. In December 2006, the program will begin in Little Rock, AR, with a health fair for state employees designed to increase awareness of health risk factors and steps to prevent disease. Beginning in early 2007, the program will reach children and their families in the Dollarway (Pine Bluff), Harrison and Paragould school districts.
There is new hope for some of the most seriously ill colon cancer patients today, following the release of a consensus statement by 72 leading oncology surgeons from 14 countries, including the United States. The Peritoneal Surface Malignancy Group (PSMG) has concluded that surgery, followed by heated chemotherapy delivered through the lower abdomen of the patient before leaving the operating room, may significantly increase the life expectancy for patients with Stage IV colorectal cancer.
The Department of Health & Human Services (HHS) Agency for Healthcare Research and Quality (AHRQ) and the Department of Defense’s military health system today released TeamSTEPPS, a new evidence-based team training and implementation toolkit that demonstrates techniques of effective communication and other teamwork skills. The new toolkit, which responds to the Institute of Medicine’s call for “interdisciplinary team training programs that incorporate proven methods for team management” to prevent medical errors, is designed to optimize team performance and outcomes across the health care delivery system.
An educational intervention program for parents of infants born prematurely that is implemented early in the Neonatal Intensive Care Unit (NICU) can reduce parental stress, depression and anxiety, enhance parent-infant interactions, and reduce hospital length of stay, according to a study led by Dr. Bernadette Melnyk, Dean and Distinguished Foundation Professor in Nursing at Arizona State University College of Nursing & Healthcare Innovation, Phoenix.
Chlamydia screening levels have increased by more than a third in the past year with nearly 100,000 young people being tested for the sexually transmitted infection through the National Chlamydia Screening Programme, Public Health Minister Caroline Flint announced today.
Pharmion Corporation (Nasdaq: PHRM) announced today the enrollment of the first patient in AVIDA(TM), a registry for patients treated with Vidaza(R) (azacitidine for injectable suspension). Vidaza was approved in May 2004 for the treatment of all five French-American-British (FAB) subtypes of myelodysplastic syndromes (MDS): refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). Myelodysplastic syndromes are a serious and life-threatening group of diseases in which the bone marrow does not function normally, resulting in the production of malformed or immature blood cells.
An educational intervention program for parents of infants born prematurely that is implemented early in the Neonatal Intensive Care Unit (NICU) can reduce parental stress, depression and anxiety, enhance parent-infant interactions, and reduce hospital length of stay, according to a study led by Dr. Bernadette Melnyk, Dean and Distinguished Foundation Professor in Nursing at Arizona State University College of Nursing & Healthcare Innovation, Phoenix.
Bristol-Myers Squibb Company (NYSE: BMY) announced data from a three-year cohort (ETV-022/901, n=119), which showed BARACLUDE? (entecavir) suppressed viral load to undetectable levels in 90 percent of nucleoside-na?ve chronic hepatitis B e-antigen (HBeAg) positive patients at week 144 who continued on-treatment from week 96. In this cohort, undetectable HBV DNA levels were defined as less than 300 copies per mL of blood as measured by polymerase chain reaction (PCR). Suppression of viral load to undetectable levels is one of several measures of antiviral treatment response; a sustained, undetectable viral load is an important goal of chronic hepatitis B treatment. The results of this three-year cohort were presented today at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).